Kehua Biotech reported the revenue of Q1

Recently, Kehua Biotech released the first quarter report of 2019. During the reporting period, the company realized the main business income of 506 million yuan, an increase of 11.8%; the net profit attributable to shareholders of listed companies was 49.58 million yuan, an increase of 2.18%; The net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, was 48.1 million yuan, a year-on-year increase of 0.62%.

At the end of the reporting period, the total assets were 3.577 billion yuan, up 2.09% from the end of the previous year; the net assets attributable to shareholders of listed companies was 2.208 billion yuan, an increase of 1.43% from the end of the previous year.During the reporting period, due to the increase in interest expense due to the growth of M&A loans, the consolidated statements increased the subsidiaries of Xi'an Tianlong, Suzhou Tianlong, Shandong Kehua and Jiangxi Kerong, resulting in a corresponding increase in sales expense management fees.

Kehua Bio said that it would continue to focus on its main business, focusing on the advantageous areas, further strengthening the synergy between the company's marketing team and channel companies, further coordinating the healthy and orderly development of the company's reagent products and instrument products, unifying market strategies, and sharing terminal resources.During the reporting period, channel companies achieved self-produced reagent sales growth of more than 50%. The company further optimized the company's molecular diagnostic business operation system and strengthened the synergy and cooperation between Kehua and Tianlong in the molecular diagnostic business. While maintaining the market share of the blood detection center of the blood center (blood station), we will actively explore the customers of biological products, and grasp the policy of achieving the full coverage of nucleic acid detection at the end of 2019, which is required by the national industry authorities, and strive for providing quality products and services for more end customers.

According to Kehua Bio's 2018 annual report, during the reporting period, the company's revenue was 1.99 billion yuan, a year-on-year increase of 24.85%, and net profit was 208 million yuan, down 4.58% year-on-year.During the reporting period, Kehua Biological invested 554 million yuan to acquire Xi'an Tianlong and Suzhou Tianlong Company. After the completion of the merger, the company's molecular diagnostic business product line was further enriched, achieving the full cover of clinical, industrial and blood station market in the field of molecular diagnostics.

Kehua Bio said that in the future, it will further focus on its main business, focus on its advantageous fields, enrich its product line, enhance its technical capabilities, and consolidate its leading position in the in vitro diagnostic reagent market. At the same time, it will actively promote the expansion strategy and further consolidate the company's in-vitro diagnostic market. The leading position, and the realization of domestic and foreign markets go hand in hand, the development of reagents and instruments, and become an IVD enterprise with international business reputation.